Cantor Fitzgerald Estimates BEAM FY2026 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Beam Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings per share of ($2.92) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.13). Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm had revenue of $7.47 million for the quarter, compared to the consensus estimate of $14.69 million. During the same period in the previous year, the company posted ($1.21) EPS. Beam Therapeutics's quarterly revenue was up 1.4% compared to the same quarter last year.

Other equities research analysts also recently issued reports about the stock. Scotiabank upgraded shares of Beam Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $40.00 target price for the company in a research note on Monday, March 10th. Wedbush reaffirmed an "outperform" rating and set a $57.00 target price on shares of Beam Therapeutics in a report on Monday, March 10th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Beam Therapeutics in a report on Monday, April 7th. Wells Fargo & Company reduced their target price on Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Finally, Barclays decreased their price target on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Beam Therapeutics has a consensus rating of "Buy" and an average target price of $48.75.

Beam Therapeutics Stock Performance

Beam Therapeutics stock traded down $0.38 during mid-day trading on Wednesday, reaching $17.06. 1,423,679 shares of the company were exchanged, compared to its average volume of 1,487,114. The firm has a market cap of $1.72 billion, a P/E ratio of -9.69 and a beta of 2.08. Beam Therapeutics has a 12-month low of $13.53 and a 12-month high of $35.25. The business has a fifty day moving average of $17.51 and a 200 day moving average of $23.12.

Insider Transactions at Beam Therapeutics

In related news, insider Christine Bellon sold 5,674 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $104,117.90. Following the transaction, the insider now directly owns 117,294 shares of the company's stock, valued at $2,152,344.90. This trade represents a 4.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John M. Evans sold 30,663 shares of Beam Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $562,666.05. Following the sale, the chief executive officer now owns 986,249 shares in the company, valued at $18,097,669.15. This trade represents a 3.02% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,771 shares of company stock worth $803,198. 3.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Beam Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company's stock worth $173,256,000 after buying an additional 1,249,303 shares during the last quarter. ARK Investment Management LLC increased its stake in Beam Therapeutics by 20.0% in the 1st quarter. ARK Investment Management LLC now owns 8,480,089 shares of the company's stock valued at $165,616,000 after purchasing an additional 1,412,060 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of Beam Therapeutics by 0.4% during the 4th quarter. Farallon Capital Management LLC now owns 8,239,123 shares of the company's stock worth $204,330,000 after buying an additional 31,000 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in shares of Beam Therapeutics by 7.9% in the first quarter. Nikko Asset Management Americas Inc. now owns 4,270,020 shares of the company's stock valued at $83,265,000 after purchasing an additional 312,409 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Beam Therapeutics by 7.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,266,871 shares of the company's stock worth $83,332,000 after buying an additional 309,260 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.